MAP kinases phosphatases (MKPs) belong to the dualspecificity phosphatase family (DUSP) and dephosphorylate phosphothreonine and phosphotyrosine within MAP kinases. We had previously shown that DUSP6/MKP-3 was phosphorylated and degraded upon growth factor stimulation, in a MEK-dependent manner. Here we show that another pathway involved in growth factor signaling, the PI3K/mTOR signaling pathway, accounts for a part of the phosphorylation and degradation of DUSP6 induced by serum growth factors, as evidenced by experiments using pharmacological inhibitors of PI3 kinase and mammalian target of rapamycin (mTOR). Moreover, specific agonists of the mTOR pathway, such as amino acids or insulin/IGF-1, which do not activate extracellular signal regulated kinases (ERKs) in our cellular model, were also able to induce the phosphorylation and degradation of DUSP6. However, a basal activity of MEK was required for the mTOR pathwaymediated phosphorylation to occur. Mutagenesis studies identified serine 159 within DUSP6 as the target of the mTOR pathway. The ERK phosphatase DUSP6 may thus constitute a novel branch-point of the crosstalk between two major signaling pathways induced by growth factors, the MEK/ERK pathway and the PI3K/mTOR pathway.
Introduction
Extracellular signal regulated kinases (ERK) are involved in numerous cellular responses, from cell growth and proliferation to cell migration, differentiation and survival (Murphy and Blenis, 2006) . ERK1/2 and ERK5 are classically activated by Ras/Raf/MEK signaling modules, upon stimulation of tyrosine kinase receptors, G protein-coupled receptors or integrins, among other stimuli. A large number of cellular responses, such as cell proliferation or differentiation, are dependent on a tight spatio-temporal control of ERK activity. The regulation of ERK signaling involves several types of ERK phosphatases, with a first wave of rapid dephosphorylation in which constitutively expressed phosphatases such as PTP-SL, STEP, He-PTP/LC-PTP are involved (Pouysse´gur and Lenormand, 2003) . In contrast, the delayed phase of ERK inactivation is dependent on gene expression and protein synthesis, and involves more specific phosphatases with a dual specificity for Ser/Thr and Tyr. They are known as MAP kinase phosphatases (MKPs) and constitute a subgroup within the dual specificity phosphatases (DUSP) family (Jeffrey et al., 2007; Owens and Keyse, 2007) . While DUSP1 (MKP-1) and DUSP4 (MKP-2), are nuclear and dephosphorylate both ERKs and the stress-activated protein kinases (SAPK) p38 and JNK, the phosphatase DUSP6 (also named MKP-3 or Pyst1) is cytoplasmic and specific to the ERKs. In vivo studies in chick, zebrafish, drosophila and mouse have highlighted a major role for DUSP6 as a negative feedback regulator of FGF signaling (Kawakami et al., 2003; Kim et al., 2004; Echevarria et al., 2005; Smith et al., 2006; Li et al., 2007) . In addition, overexpression of DUSP6 in Ras-transformed cells prevents their growth in nude mice (Marchetti et al., 2004) .
We had previously shown that DUSP6 was phosphorylated in response to serum or growth factors, in a MEK-dependent manner. Phosphorylation occurred on two serine residues, Ser159 and Ser197, and caused DUSP6 degradation through the proteasome (Marchetti et al., 2005) . In the present study, we show that DUSP6 phosphorylation induced by growth factors is also dependent on the PI3K/mTOR pathway. Moreover, DUSP6 is also phosphorylated when mammalian target of rapamycin (mTOR) is more specifically activated by amino acids, insulin or IGF, which do not activate ERK in the cells used in our study. Several lines of evidence suggest that a basal activity of MEK/ERK favors the mTOR-dependent phosphorylation. Finally, this phosphorylation targets serine 159 and is associated with increased degradation of the protein.
Results

Phosphorylation of DUSP6 by growth factors is blocked by PI3K or mTOR inhibition
We have previously shown that serum growth factors induced the phosphorylation of the ERK phosphatase DUSP6/MKP-3 (Marchetti et al., 2005) . Both endogenous and tetracycline-induced forms were phosphorylated and degraded in serum-stimulated R443 cells (derived from CCL39 hamster fibroblasts). Phosphorylation was most evident when cells were first starved for growth factors and restimulated by serum, and appeared as a shift in the apparent molecular weight of DUSP6 (see Figure 1a ) that could be reverted by calf intestine phosphatase and was blocked by U0126, a MEK inhibitor (Marchetti et al., 2005) . In the present work, either U0126 (10 mM) or PD184352 (2 mM) were used for blocking the MEK/ERK pathway, giving similar results. Using the same tetracycline-inducible cell system, we first confirmed our previous results (Marchetti et al., 2004 (Marchetti et al., , 2005 ) that tetracycline-induced DUSP6 inhibits ERK phosphorylation in response to serum growth factors (47% inhibition, see Figure 1a ). We now also show that serum-induced phosphorylation is not only blocked by U0126 but also partially blocked by the mTOR inhibitor rapamycin. Concomitant use of both U0126 and rapamycin was most efficient in blocking the shift of DUSP6 ( Figure 1a) . As a control, rapamycin efficiently prevented the phosphorylation of p70 S6K, a downstream target of mTOR, as evaluated by the shift of the total p70 S6K protein (Figure 1b) . In contrast, rapamycin had no significant effect on ERK phosphorylation. Similar results were obtained with a PI3K inhibitor, LY294002 (not shown).
Other growth factors were tested for their ability to phosphorylate DUSP6, and in particular, growth factors that are known to efficiently signal to PI3K/mTOR. Insulin ( Figure 1c ) and IGF-1 (Figure 1d ), although they do not activate ERK in those cells, induced a partial phosphorylation of DUSP6. This event was inhibited not only by rapamycin but also by U0126, suggesting that a basal activity of ERKs is required for the mTOR-mediated phosphorylation to occur. Platelet-derived growth factor (PDGF), which efficiently signals to both the MEK/ERK and the PI3K/mTOR pathways, also induced the phosphorylation of DUSP6 (not shown).
Importantly, DUSP6 was phosphorylated by growth factors in two other cell types engineered for tetracycline-dependent expression, the LS174 (Figure 1e ) and A375 cell lines (not shown). Phosphorylation followed exactly the same pattern as in R443 cells, being blocked both by U0126 and rapamycin. These results indicate that DUSP6 phosphorylation by the mTOR pathway is not specific to R443 cells. mTOR-dependent phosphorylation occurs in the N-terminal domain of DUSP6 In our previous work, we had produced a truncation mutant of DUSP6 that was deleted of the catalytic domain and the C-terminal part of the molecule (Figure 2a ). This mutant, named DUSP6-D229, was shown to be phosphorylated by serum growth factors in a way similar to the full-length molecule (Marchetti et al., 2005) . In the present study, it helped to analyse more precisely the effects of kinase inhibitors on the extent of phosphorylation.
The R443 cells used in this study also express a DRaf-1:ER chimera that allows direct activation of the MEK/ERK pathway by tamoxifen, which in turn induce the phosphorylation of DUSP6 (Marchetti et al., 2005) . Figure 2b shows that DRaf-1:ER stimulation by tamoxifen produced a phosphorylation of DUSP6-D229 that was completely blocked by the MEK inhibitor PD184352 and partially by rapamycin. A confirmation of the involvement of mTOR in DRaf-1:ER-induced signals was provided by a modest but detectable phosphorylation of p70 S6K on threonine 389, a well-characterized target of the mTOR pathway. Such type of phosphorylation of S6 kinase in response to the stimulation of DRaf1:ER has been described previously (Lenormand et al., 1996) . As mentioned above, activation of mTOR by DRaf-1:ER is probably mediated by an ERK-dependent phosphorylation and inactivation of TSC2, as described by Ma et al. (2005) . tetracycline, and pretreated for 30 min with either 10 mM U0126 or 40 nM rapamycin before stimulation with 10% fetal bovine serum (a, b, e), 50 nM insulin (c) or IGF-1 (d) for 30 min ('C': control, unstimulated cells). Cells were then lysed in Laemmli buffer and the phosphorylation of DUSP6, ERK1/2 and p70 S6K analysed by western blotting. Levels of total ERKs were taken as control to quantify the extent of ERK1/2 phosphorylation with Gene Tool. Values of quantification are given below the western blot for pERK1/2, taking ERK phosphorylation in the absence of tetracycline as 100% control.
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The phosphorylation of DUSP6-D229 by PDGF or serum was similar to that of full-length DUSP6, and was dependent on both MEK/ERK and mTOR, with the phosphorylation being most efficiently blocked when cells were treated simultaneously with both inhibitors (Figure 2c ). IGF-1 was slightly less efficient than serum or PDGF in stimulating DUSP6-D229 phosphorylation, perhaps because it does not activate ERKs in these cells (see Figure 5 ). But in this case again, both the MEK inhibitor and rapamycin inhibited DUSP6 phosphorylation by IGF-1, although the combination of both inhibitors was apparently most efficient.
Amino acids constitute another way to selectively activate the mTOR pathway (for a review, see Avruch et al., 2006) . Figure 2d shows that the addition of amino acids to nutrient-starved cells induced a phosphorylation of DUSP6-D229 that was completely blocked by rapamycin, and also by the MEK inhibitor U0126. In this cell system, amino acids do not significantly activate ERK, but, as mentioned earlier, this result suggests that a basal activity of ERK is required for the mTORdependent phosphorylation to occur.
The mTOR-dependent phosphorylation occurs on serine 159
We had formerly shown that serines 159 and 197 contained in the DUSP6-D229 truncation mutant were phosphorylated in response to serum growth factors. Their mutations prevented both the phosphorylation and the degradation of DUSP6 induced by serum (Marchetti et al., 2005) .
Here we show that both U0126 and rapamycin blocked the shift of the DUSP6-S197A, in which serine 159 is intact ( Figure 3) . Thus, the phosphorylation of this mutant, which behaved apparently as the wild-type form, is dependent on both MEK/ERK and mTOR signaling. In contrast, although the shift of the DUSP6-S159A mutant produces a more diffuse signal difficult to visualize, it was clear that U0126, but not rapamycin, was able to prevent the shift of this mutant. Finally, the mutation of both serines (DUSP6-DM, for Double Mutant) prevented any shift of the molecule in response to serum.
Altogether, these findings indicate that (1) only the DUSP6-S197A mutant remains sensitive to mTOR inhibition while DUSP6-S159A is not, suggesting that the mTOR-dependent phosphorylation occurs on serine 159 and not on serine 197 and (2) that MEK/ERK activity is required for the mTOR phosphorylation to occur as evidenced by the results obtained with the DUSP6-S197A mutant, which cannot be phosphorylated in the absence of MEK activity.
The mTOR pathway is involved in the proteolysis of DUSP6 induced by growth factors Our former work had shown that growth factors induced a proteasome-mediated degradation of DUSP6 that could be blocked by MEK inhibitors (Marchetti et al., 2005) . We therefore investigated whether rapamycin had an effect on DUSP6 stability.
Cells were starved, treated with cycloheximide to prevent de novo protein synthesis, pretreated either by PD184352, rapamycin or both and stimulated with serum up to 3 h. Because cycloheximide causes amino acid accumulation inside the cell, it is able, at high concentrations, to activate mTOR. In pilot experiments, tetracycline, pretreated with either 2 mM PD184352 or 40 nM rapamycin and treated with either 1 mM 4-OHT (b), 10 ng ml À1 PDGF, 10% fetal bovine serum or 50 nM IGF-1 (c). Cells were then lysed in Laemmli buffer and the phosphorylation of DUSP6-D229 and p70 S6K analysed by western blotting. For (d), cells were treated overnight in the presence of 1 mg ml À1 tetracycline, in a medium deprived in serum and amino acids. Cells were then pretreated with MEK or mTOR inhibitors, and stimulated with amino acids or fetal bovine serum for 30 and 60 min. Cell lysates were analysed for DUSP6 and ERK phosphorylation.
Phosphorylation and degradation of DUSP6 by the mTOR pathway O Bermudez et al we first determined that a concentration of 5 mg ml À1 of cycloheximide was optimal to inhibit protein synthesis in these cells without significantly stimulating mTOR (not shown). Moreover, proteins were separated on 12% acrylamide sodium dodecyl sulfate-polyacrylamide gel electrophoresis, to allow concentration of the DUSP6 signal in a sharp band for adequate quantification. For this reason, protein shifts are generally not detected on these western blots.
In serum-starved conditions (NS), a basal proteolysis of DUSP6 occurs (Figure 4a) , of which the extent may vary with the experiments. It is likely to correspond to an auto production of growth factors by the cells as basal DUSP6 degradation was efficiently blocked when control cells were pretreated with both MEK and mTOR inhibitors. Nevertheless, serum caused a much more rapid proteolysis of DUSP6, which paralleled with increased phosphorylation of ERKs and p70 S6K. In accordance with our previous work, cell pretreatment with the MEK inhibitor PD184352 clearly diminished DUSP6 degradation, and similar results were obtained with U0126, another inhibitor of MEK. We show now that the mTOR inhibitor rapamycin significantly increased the stability of the phosphatase, although it seemed to be less efficient than PD184352, especially at early time points. Moreover, in contrast to the MEK inhibitor, rapamycin had no apparent effect on phospho-ERK, indicating that the inhibition of DUSP6 degradation was not due to an indirect effect of mTOR on the MEK/ERK pathway. In contrast, the phosphorylation of p70 S6K at threonine 389 was blocked by rapamycin, but not PD184352, as expected. When cells were pretreated with both inhibitors, additive effects could be observed on DUSP6 stability. Nevertheless, partial degradation remained in serum-treated cells, even in the presence of both inhibitors, suggesting that these may not be fully effective in blocking the high signals provided by serum growth factors, or that other mechanisms may regulate the degradation of DUSP6.
It is difficult to compare directly the half-life of DUSP6 different mutants with their wild-type counterpart as they are expressed in different cell clones, which have their own intrinsic characteristics. However, it is pertinent to compare the relative sensitivity of DUSP6 mutants toward MEK or mTOR inhibition, by testing the stability of each mutant in its own cellular context, in the presence or absence of MEK or mTOR inhibitors. Figure 4b shows that the degradation of DUSP6-S197A induced by serum was partially inhibited by the MEK inhibitor PD184352 as well as rapamycin, and more efficiently when both inhibitors were used simultaneously. This result indicates that the phosphorylation of serine 159, which is intact in this mutant, induces a degradation that is dependent on both MEK and mTOR. In contrast, the mutant DUSP6-S159A was protected from degradation by PD184352 but no longer by rapamycin (Figure 4c ), indicating that the phosphorylation of serine 197 and the subsequent degradation of DUSP6 is not dependent on mTOR, but only on MEK activity. This finding is in agreement with the results obtained with the shift assays (see Figure 3) . The stability of the double mutant of DUSP6, in which both serines are mutated to an alanine, was not significantly affected by serum (not shown), as previously described in Marchetti et al. (2005) .
IGF-1 promotes DUSP6 degradation
Finally, we tested whether activation of mTOR by IGF-1, which do not activate ERKs per se in the cells we used, could be sufficient to induce DUSP6 degradation. Figure 5 shows that, in contrast to serum, IGF-1 did not increase ERK phosphorylation above the minimal activity found in starved cells. It however stimulated the phosphorylation of p70 S6K on Thr389, the target of mTOR, and, most importantly, induced a degradation of DUSP6 that was intermediate to that observed in control (unstimulated) conditions and that were induced by serum ( Figure 5 ).
Discussion
We had previously shown that the ERK phosphatase DUSP6 was phosphorylated and degraded when cells Figure 4 Both the MEK/ERK and the mTOR pathways play a role in the degradation of DUSP6 induced by serum growth factors. Cells were starved overnight in the presence of 1 mg ml À1 tetracycline, pretreated with 5 mg ml À1 cycloheximide for 30 min and with 2 mM PD184352 (P) or 40 nM rapamycin (R) and treated or not treated with 10% fetal bovine serum for various time up to 3 h. Cells were then lysed in Laemmli buffer and the amount of DUSP6, as well as the phosphorylation state of ERK1/2 and p70 S6K were analysed by western blotting. Amounts of DUSP6 wild type (WT; a), DUSP6-S197A (b) and DUSP6-S159A (c) were quantified using Gene Tools as described in Materials and methods with ARD1 levels taken as a loading control. Each graph is representative of four different experiments.
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O Bermudez et al were stimulated by serum growth factors. The MEK/ ERK pathway was shown to be involved in this regulation in which two serines in the N-terminal domain of DUSP6, Ser159 and Ser197, were phosphorylated (Marchetti et al., 2005) . Now we show that another signaling pathway activated by many growth factors, the PI3K/mTOR pathway could phosphorylate and degrade DUSP6, serine 159 being the targeted amino acid. These results highlight a novel crosstalk between two fundamental pathways in cell signaling, the ERK pathway and the mTOR pathway. Although rapamycin clearly blocks the phosphorylation of DUSP6 induced by growth factors or amino acids, we cannot rule out the possibility that another kinase, downstream of mTOR in the pathway, may be responsible for the phosphorylation of DUSP6. It is difficult to identify a clear canonical TOR Signaling (TOS) motif in the peptidic sequence of DUSP6, at least in the way these motives were described previously (Schalm and Blenis, 2002; Land and Tee, 2007) . Alternatively, the p70 S6 kinase could be the kinase that phosphorylates DUSP6 as it was shown to phosphorylate not only the ribosomal protein S6 but also several cytoplasmic or membrane proteins, such as IRS1 (Harrington et al., 2004) . We have tried to knockdown the two isoforms of S6 kinases using siRNA but we have not succeeded in reducing the total amounts of S6 kinases more than 70%, which is not sufficient to study the effects of these siRNA on DUSP6 phosphorylation (unpublished results). mTOR-dependent phosphorylation was induced by growth factors that activated or not activated the MEK/ ERK pathway, and also by amino acids, more specific activators of mTOR. Although the data obtained with serum or PDGF support a role for additive effects of MEK and mTOR inhibitors on the phosphorylation of DUSP6 (the combination of both being more efficient than each taken separately), it seems that the inhibition of MEK is nevertheless more efficient in blocking DUSP6 phosphorylation than the inhibition of mTOR. This was especially obvious when cells were treated with amino acids, or when the phosphorylation and degradation of the single mutant DUSP6-S197A were investigated. The latter even suggests that the degradation of DUSP6 induced by the mTOR pathway is blocked when MEK is inhibited. Thus, a basal MEK activity may favor the phosphorylation of DUSP6 by the mTOR pathway, or even be a prerequisite in certain conditions. Several hypothesis may explain this finding. First, a dependency of the mTOR-mediated phosphorylation may be related to a role for ERKs in the regulation of the mTOR signal itself. Ma et al. (2005) have shown that ERKs are able to activate mTOR by phosphorylating and inhibiting the mTOR inhibitor TSC2. Such a MEK/ ERK dependent activation of mTOR was actually also observed in the present work, where the specific activation of a DRaf-1:ER chimera produced a mild phosphorylation of p70 S6 kinase on mTOR-dependent threonine 389. As expected, this phosphorylation was blocked by both MEK and mTOR inhibitors (see Figure 2) . However, when serum growth factors that strongly activated the PI3K/mTOR pathway were used, the inhibition of MEK had no significant impact on the phosphorylation of p70 S6K on threonine 389 (as shown in Figure 4 , top panel). The possibility that the mTOR pathway should absolutely be stimulated by ERKs to be active in this context is therefore highly unlikely.
Another explanation suggests sequential phosphorylation events, with ERK mediating the first phosphorylation and the mTOR pathway a second phosphorylation of DUSP6. However, serine 159, the mTORsensitive residue, can still be phosphorylated when serine 197 is mutated to an alanine, which also makes the 'conditional phosphorylation' model unlikely. Finally, there might be a role for ERKs in inducing conformational changes in the DUSP6 molecule that would favor its phosphorylation by a kinase of the mTOR pathway. ERKs were shown, several years ago, to bind and to reveal the catalytic activity of DUSP6.
In vitro experiments have indicated that the kinase activity of ERK was not required for this activation process to occur (Camps et al., 1998) . However, it is difficult to definitely rule out the possibility that activated ERKs may favor the formation of the ERK/ DUSP6 complex in intact cells, where proteins are less in excess than in vitro. Alternatively, such interactions may be favored by the formation of a scaffold involving several players of the MEK/ERK pathway and dependent on the MEK activity itself. À1 tetracycline, pretreated with 5 mg ml À1 cycloheximide for 30 min and treated with either 10% fetal bovine serum or 50 nM IGF-1 for various time up to 3 h. Cells were then lysed in Laemmli buffer and the protein levels of DUSP6, as well as the phosphorylation state of ERK1/2 and p70 S6K were analysed by western blotting. Protein levels of ARD1 were used a loading control. Amounts of DUSP6 protein were quantified using Gene Tools as described in Materials and methods.
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In our previous work (Marchetti et al., 2005) , we had shown that the mutation of both serines 159 and 197 did not affect the phosphatase activity of DUSP6 toward ERKs in serum-stimulated cells. Thus, mTOR is unlikely to affect the catalytic activity of DUSP6 per se. Rather, we demonstrated that serum growth factors affect the stability of the phosphatase. Not only the MEK/ERK pathway but also the mTOR pathway plays a role in the regulation of DUSP6 half-life. However, the protective effect of rapamycin on DUSP6 stability was not associated with a detectable change in ERK phosphorylation, even after several hours of stimulation by growth factors. On the one hand, this rules out the hypothesis that rapamycin would protect DUSP6 from degradation through an indirect inhibition of ERKs. In this respect, it provides specificity to the mechanism, and uncouples the ERKinduced degradation of DUSP6 from that caused by mTOR activation. On the other hand, it may seem surprising not to observe any impact of DUSP6 stabilization on ERK phosphorylation. One explanation may be that the activation of ERK by serum is strong and difficult to inhibit. Alternatively, impact on phospho-ERK may also be restricted to certain subcellular compartments (Murphy and Blenis, 2006; McKay and Morrison, 2007) and masked when total cell lysates are analysed.
ERKs have numerous molecular targets, some of them being involved in the production of metabolites prior to cell division, as well as in protein translation (Chambard et al., 2007) . The latter is also regulated by molecular players of the mTOR pathway (Averous and Proud, 2006; Mamane et al., 2006) . In this respect, protein translation is a major example of collaboration between the MEK/ERK and the mTOR pathway, in which the cell synthesizes sufficient proteins for division. This collaboration occurs not only at the level of translation factors but also more upstream in the pathways, at the level of TSC2 for example, which is phosphorylated and inhibited by ERKs, resulting in subsequent activation of mTOR (Ma et al., 2005) . Here we have identified a novel molecule involved in the crosstalk between the two signaling systems, the ERK phosphatase DUSP6. This crosstalk might be particularly relevant in cells that display high levels of PI3K/ mTOR activity, such as cancerous cells harboring mutations or amplifications in components of this pathway, and participate in the deregulation of ERK signaling.
Materials and methods
Materials
Tetracycline, 4-hydroxytamoxifen and rapamycin were obtained from Sigma (Saint-Louis, MO, USA) and U0126 from Calbiochem/Merck Chemicals Ltd., Nottingham, UK). PD184352 was a kind gift of Dr Michiaki Kohno (Nagasaki University, Japan). Recombinant human PDGF-BB was obtained from Peprotech Inc. (London, UK), recombinant human insulin and recombinant human IGF-I from Tebu (Le Perray-en-Yvelines, France).
Antibodies
The monoclonal antibody directed against the dual-phosphorylated ERK1/2 was purchased from Sigma. The phosphop70 S6 kinase (Thr389) antibody was purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-ARD1 antibody was produced in our laboratory. HRP-conjugated anti-mouse and anti-rabbit antibodies were purchased from Promega (Charbonnie`res, France).
Cell culture and transfection
The parental clone R443, a derivative of the CCL39 hamster fibroblast cell line expressing the DRaf1:ER chimera and the Tet repressor, was described previously, as well as the production of clones expressing wild-type or mutant DUSP6 in this background (Marchetti et al. 2005) . These cells were grown in phenol red-free Dulbecco's modified Eagle's medium (DMEM) medium containing 7.5% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) and supplemented with glutamax (Invitrogen) and 20 mM glucose. LS174 cells and A375 cells expressing the Tet repressor were a kind gift of Dr M van de Wetering (Utrecht, The Netherlands) and Dr Emmanuel Vial (our laboratory), respectively. They were grown in DMEM containing 10% FBS. All cell lines were transfected, using the calcium phosphate method, with the pcDNA4/TO-DUSP6(MKP-3) plasmid described previously (Marchetti et al., 2005) . Zeocine-resistant clones were screened by immunofluorescence and western blotting, in the presence or absence of tetracycline (1 mg ml À1 ; Invitrogen).
Western blotting
Tetracycline-inducible cells were seeded in 24-well culture plates at a density of 10 5 cells per well and grown for 48 h in DMEM medium containing FBS. For phosphorylation or stability experiments, cells were serum starved for 20 h in the presence of 1 mg ml À1 of tetracycline to induce transgene expression. Cells were then stimulated for the indicated time, with either 10% FBS, 1 mM 4-hydroxytamoxifen (for the activation of the DRaf-1:ER chimera), 10 ng ml À1 PDGF, 50 nM of IGF or insulin. In some experiments, cells were pre-incubated for 30 min with cycloheximide (5 mg ml
À1
) and/or kinase inhibitors. After two washes with phosphate buffered saline (PBS), cells were immediately lysed in Laemmli sample buffer. Proteins were quantified with a BCA kit (Sigma), resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 10% gels (37.5:1 acrylamide/bisacrylamide) and transferred onto PVDF membranes (Immobilon-P; Merck-Eurolab Polylabo, Strasbourg, France). Membranes were incubated with the appropriate specific primary antibody followed by the corresponding horseradish peroxidase-conjugated secondary antibody and proteins were detected by enhanced chemiluminescence (Amersham Biosciences). When indicated, protein levels were quantified using the Gene Tools software from Syngene.
Cells were treated similarly for the experiments with aminoacid stimulation, except that they were first grown in medium deprived in both serum and amino acids (Invitrogen), before being re-stimulated with a mix (1:1) of essential and nonessential amino acids (Invitrogen).
